The Innovative Fresh Start Private Implant Procedure
Fresh Start is the only alcohol treatment program in the world to offer a single-administration, long-acting, naltrexone implantT procedure that has been approved for use by a regulatory body. *This novel and highly effective* treatment delivers target therapeutic levels of naltrexone for an average of approximately 200 days. **via an innovative implant procedure developed by Dr. George O'Neil** Once implanted, it eliminates the need for the patient to choose or remember to take naltrexone on a daily basis.
In a minimally invasive, outpatient procedure, trained medical doctors at an independent clinic which forms part of the FSP network in America insert a specially formulated, biodegradable naltrexone implant just beneath the skin below the patient’s lower abdominal area. The procedure is rapid and requires only local anesthetic. Patients are awake during the short procedure and have reported minimal to no physical discomfort.
In nearly every instance, patients are released the same day as the procedure and allowed to return to their recovery suites with their accompanying recovery partner. A recovery partner, while often a spouse or significant other, can be any capable adult selected by the patient.
Patients have typically reported complete freedom from alcohol cravings within hours of the procedure and a return to normal physical activity by the next day. The rapid-onset of the medication, and the short recovery period allows patients and their loved ones to immediately begin healing and working together towards an alcohol-free life. To facilitate a complete and permanent recovery, patients and their families and friends immediately initiate the Fresh Start Coaching Program.
* Fresh Start does not render medical advice or services. Individuals should consult their physicians or other competent medical professionals to determine if Fresh Start's progarm is right for them.
** Addiction Biology (March 2004) 8, 65-70. G.K. Husle, D.E. Arnold-Reed. G. ONeil, C-T. Chan & R.C. Hansson









